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Organophosphate (OP) exposure can be lethal at high doses while lower doses may impair performance of critical tasks. The ability to predict such
effects for realistic exposure scenarios would greatly improve OP risk assessment. To this end, a physiologically based model for
diisopropylfluorophosphate (DFP) pharmacokinetics and acetylcholinesterase (AChE) inhibition was developed. DFP tissue/blood partition
coefficients, rates of DFP hydrolysis by esterases, and DFP-esterase bimolecular inhibition rate constants were determined in rat tissue
homogenates. Other model parameters were scaled for rats and mice using standard allometric relationships. These DFP-specific parameter values
were used with the model to simulate pharmacokinetic data from mice and rats. Literature data were used for model validation. DFP concentrations
in mouse plasma and brain, as well as AChE inhibition and AChE resynthesis data, were successfully simulated for a single iv injection. Effects of
repeated, subcutaneous DFP dosing on AChE activity in rat plasma and brain were also well simulated except for an apparent decrease in basal AChE
activity in the brain which persisted 35 days after the last dose. The psychologically based pharmacokinetic (PBPK) model parameter values
specific for DFP in humans, for example, tissue/blood partition coefficients, enzymatic and nonenzymatic DFP hydrolysis rates, and bimolecular
inhibition rate constants for target enzymes were scaled from rodent data or obtained from the literature. Good agreement was obtained between
model predictions and human exposure data on the inhibition of red blood cell AChE and plasma butyrylcholinesterase after an intramuscular injection
of 33 pg/kg DFP and at 24 hr after acute doses of DFP (10-54 pg/kg), as well as for repeated DFP exposures. The PBPK model for DFP was also
adapted for the purpose of modeling parathion, including its metabolism to the toxic daughter product paraoxon. The development and
validation of this PBPK model for two OPs provides a basis for studying the kinetics and in vivo metabolism of other bioactivated organophosphate
pesticides and their pharmacodynamic effect in humans. - Environ Health Perspect 102(Suppl 11):51-60 (1994)
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Introduction
A variety oforganophosphate (OP) esters
inhibit acetylcholinesterase (AChE) in both
central and peripheral nervous tissues result-
ing in excessive buildup ofacetylcholine at
neural receptors (1). AChE accumulation
causes a spectrum of acute toxic effects
mediated by the nicotinic, muscarinic, and
central nervous system interactions of
acetylcholine. These range, depending on
dose, from subclinical performance decre-
ments to convulsions, asphyxia, and death
(2). A model capable ofpredicting the rela-
tionship between OP exposure and resultant
toxic effects would be useful in risk assess-
ment and the design ofmeasures protective
against exposure to cholinesterase inhibitors.
Ideally, the model should be amenable to
cross-species scaling and accurately predic-
tive outside the dose range over which its
primary validation studies were conducted.
Physiologically based pharmacokinetic
(PBPK) models meet these criteria (3-7).
They consist ofdescriptions ofthe physiol-
ogy ofthe exposed organism and the bio-
chemical processes, which are quantitatively
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important determinants oftoxicant disposi-
tion. This includes parameters describing
tissue solubilities, metabolism, and binding
ofthe toxicant. A number ofPBPK models
have been developed for solvents and rela-
tively stable halogenated compounds
(5,8,9). Additionally, an in vitro kinetic
model for diisopropylfluorophosphate
(DFP) in rat brain has been developed (10),
and a PBPK model for single dose pharma-
codynamics of soman in rats was recently
published (11).
The goal ofthis study was to develop a
quantitative, physiologically based model of
OP pharmacokinetics andAChE inhibition.
While AChE inhibition is not a toxic effect
per se, it is an index ofthe probability that
acute OP toxicity will occur (12). DFP is
not itselfcommercially important, but was
chosen for this study as its mechanism of
action is thought to be representative of
other highly toxic OPs (12). Parathion (PA)
is an organophosphate insecticide that owes
its toxicity to the oxidized product of
parathion, paraoxon (PO). The metabolism
ofPAtakes place predominantly in the liver,
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but it is also thought that some metabolism
ofparathion occurs in extrahepatic tissues.
The basic model structure described herein
for DFP and parathion should be applicable
to other OPs whose acute toxicity is medi-
ated by inhibition ofAChE.
Development ofthe
Physiologically Based
Pharmacokinetic Model
Elements ofModelStructure
(Overview)
The major determinants ofDFP disposition
in vivoare its hydrolysis by esterases, binding
to esterases, tissue solubility, and volatility
(leading to exhalation). DFP is metabolized
(hydrolyzed) byA esterases (AEST) to a non-
inhibitory product, diisopropylphosphoric
acid (DIP). This organophosphate ester also
binds to B esterases (BEST) and inhibits
their enzymatic activity. The hydrolysis reac-
tion is governed by Michaelis-Menten kinet-
ics whose Vma. and K were determined
with in vitro assays (Appendix 1). Those
compartments described in the model as
having A esterase activity (DFPase) are
shown in Figure 1 as shaded areas. The bind-
ing to and inhibition of B esterases were
modeled as bimolecular reactions and were
also determined from in vitrostudies (Tables
Figure 1. Diagram of the physiologically based phar-
macokinetic model for diisopropylfluorophosphate
(DFP). The shaded tissue compartments indicate
organs within the model in which DFP-ase activity is
described. Arrows in and out of the lung compartment
indicate inhalation and exhalation of DFP.
1 and 2). All tissue compartments in the
model except fat were described as having B
esterase activity (13). The major determi-
nants ofparathion and paraoxon disposition
in the model are metabolism ofparathion to
Table 1. Metabolic constants for pharmacokinetic model ofdiisopropylfluorophosphate.
Organ
Brain
Liver
Kidney
Richly perfused
Venous blood
Arterial blood
Mouse
Vmax, mg/hr Km, mg/l
2.28 439.80
256.58 237.36
25.61 134.3
2.72 50.89
79.38 198.70
26.46 198.70
Rat
Vmax, mg/hr Km, mg/I
9.18 439.80
1380.00 237.36
103.32 134.3
11.04 50.89
320.18 198.7
106.73 198.7
Human
Vmax, mg/hr Km, mg/l
668 440
52474 237
5042 134
560 51
616 199
216 199
Bimolecular rate constants, pM-1 hr-1
Acetylcholinesterase
14.16
Butyrylcholinesterase
Fast 354.00
Slow 30.00
Carboxylesterase
Fast 1.10
Slow 0.52
Table 2. Metabolic constants for a pharmacokinetic model of parathion.
Parathion desulfuration Parathion dearylation Paraoxon hydrolysis
Organ Vmax, mg/hr Km, mg/l Vmax, mg/hr Kn, mg/l Vmax, mg/hr Kn, mg/I
Brain - 9.2 440
Liver 16.6 3.0 28.4 81.8 11 50
Kidney - 103 134
Richly perfused - 11 50
Venous blood 150 170
Arterial blood - 100 170
paraoxon, hydrolysis of paraoxon by
esterases, binding ofparaoxon to esterases,
and the tissue solubility ofthe parent and
daughtercompound.
Hydrolysis of
DiisopropyIfluorophosphate
DFP is rapidly hydrolyzed by A esterases
(14). These enzymes are present in virtually
all tissues but often have high activity in the
blood. As a result, blood AEST strongly
affects the amount ofDFP reaching AChE
in target tissues. The activity ofAEST was
obtained from laboratory studies in the rat
as described below. The Michaelis-Menten
constants K and VmaX were determined for
AEST activity in rat brain, blood, liver, and
kidney. The Km for AEST in each ofthese
tissues was assumed to be the same for each
of the corresponding mouse tissues. V1a.
values for each ofthe corresponding mouse
tissues were scaled to the 0.7 power ofbody
weight (8). DFP also undergoes sponta-
neous hydrolysis in aqueous solutions. A
pseudofirst-order rate of spontaneous
hydrolysis was estimated in heat treated (30
min at 60°C) homogenates ofeach tissue
(10) and was found to be insignificant
(0.0046 min-' relative to the enzymatic
rates ofDFP hydrolysis (15).
Hydrolysis ofParaoxon
The hydrolysis of paraoxon by A esterases
was described with Michaelis-Menten
kinetics, using data from Wallace and
Dargan (16), Chemnitius et al. (17), and
Pla andJohnson (18).
Diisopropylfluorophosphate
BindingtoEsterases
The schema for model simulations offree
B esterase, in this case AChE, is shown in
Figure 2. The amount of free AChE is
determined by the concentration of DFP
and 4 different rate constants. The basal
level of AChE results from a balance
between basal degradation ofAChE and
synthesis ofnew enzyme. After exposure to
DFP, the amount offreeAChE is governed
by the balance between the bimolecular
rate of inhibition and the rate at which
inhibited AChE is regenerated. Once
Synthesis
of NewAChE Biomolecuar
4 Rate of AChE Rate of
Inhibtn AChE
DFP Free Inhibited Ag "Aged'
AChE AChE AChE
Regeneration
of Bound
Basal AChE
Degradation of AChE
Figure 2. Model for acetylcholinesterase (AChE) inhib-
tion, aging, regeneration, synthesis, and degradation.
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AChE is inhibited, it will either return to
free AChE, or age and form a permanently
inhibited enzyme.
B esterases (19) have a serine residue at
the catalytic site to which OPs bind, inacti-
vating the enzyme. BESTs include AChE,
butyrlcholinesterase (BChE), and car-
boxylesterase (CaE). While AChE is the
target in acute OP intoxication, DFP bind-
ing to BChE and CaE is without adverse
physiological effect (20). Phosphorylated
BESTs undergo spontaneous hydrolysis,
leading to regeneration of the active
enzyme (Figure 2). For DFP, however, this
process is relatively slow (21) (Table 3).
Phosphorylated BEST may also undergo
aging (22), resulting in a permanent loss of
activity (Figure 2). BEST activities were
obtained from Maxwell et al.(13).
Basal activities ofAChE, BChE, and
CaE were defined by zero-order synthesis
rates (moles bindinF sites/hour) and first-
order loss rates (hr ; Table 3). First-order
loss of rat brain AChE was obtained from
Wenthold (23), who used radiolabled pre-
cursors ofAChE to determine enzyme
degradation. Synthesis of rat plasma and
brain AChE was determined from model
optimization ofthe data ofMichalek (24),
Traina and Serpietri (25). The zero-order
synthesis rates and first-order loss rates for
BESTs in rat plasma and in mice were esti-
mated by fitting simulations to data
describing the rate of return of enzyme
activity to normal levels over time after
DFP dosing (see "Results"). The synthesis
and loss rates used forAChE were also used
for BChE and CaE since the rate of
increase ofthese activities after OP inhibi-
tion is close to that ofAChE (25,26).
Paraoxon Bindingto Esterases
The activity of esterases which are inhib-
ited by paraoxon were obtained from
Maxwell (13).
Metabolism ofParathion to Paraoxon
The metabolism of parathion to its toxic
daughter product paraoxon was described
in the model to occur in the liver and the
kidney by Michaelis-Menten kinetics. The
initial K and V for this metabolism m max
were obtained from the work ofWallace
and Dargan (16). These rates of metabo-
lism were optimized to provide better pre-
dictions of parathion and paraoxon
pharmacokinetics.
Specification ofCompartments
The PBPK model for DFP consisted of
both organ-specific and lumped compart-
ments (Figure 1; Appendix 2; Table 4).
Table 3. Model parameters forAChE inhibition.
Mouse Rat Human
Enzyme inhibition, pM-1 hr-1 14.16 14.16a 14.16
Enzyme regeneration, hrK1 0.016 0.016b 0.016
Enzyme aging, hr1 0.297c 0.263c 0.150
Enzyme synthesis, nmole/hr
Plasma 0.0003 0.19e 0.053
Brain 0.0025d 0.0014f 0.0014
Enzyme degradation, hr
Plasma 0.060Od 0.D1e 0.200
Brain 0.070d 0.0109 0.010
aData from Jepson (10). bData from Vandekar and Heath (21). CData from Andersen et al. (40). dData from Martin
(34). "Data from Traina and Serpietri (25). 'Data from Michalek et al. (24). gData from Wenthold et al. (23). The
model tracked the inhibition of B esterases in brain, plasma, lung, diaphragm, kidney, liver, and slow and fast
compartments. Data and model simulations are shown onlyfor brain and plasma.
Organ-specific compartments were used to
describe those tissues directly involved in
acute DFP toxicity (e.g., brain, lung,
diaphragm) or those expected to
significantly influence DFP pharmacokinet-
ics (e.g., blood, fat). Blood, though not a
target organ, is an important site of DFP
metabolism, and blood AChE is a useful
reflection ofAChE activity in less accessible
organs. Separate venous and arterial com-
partments were used because it has been
shown experimentally that there can be
significant arterial-venous differences in
DFP concentrations (27). The kidney and
liver are also sites ofenzymatic hydrolysis of
DFP for which tissue-specific metabolic
parameters were readily obtainable. Lumped
compartments (fat, rapidly perfused, etc.)
were used to describe remaining tissues. The
rapidly perfused lumped compartment rep-
resented viscera not explicitly described else-
where. The slowly perfused compartment
denoted mainly muscle tissue distributed
throughout the organism. Use oflumped
compartments helped to preserve a balance
between parsimony ofmodel structure, to
maintain chemical mass balance, and to
describe explicitly mammalian physiology
and biochemistry that determine the phar-
macokinetic behavior ofOPs.
The PBPK model consisting of mass-
balance differential equations and associ-
ated computer programs that describe the
time-dependent pharmacokinetics of DFP
and inhibition ofAChE were written in
Advanced Continuous Simulation
Language (ACSL)(Mitchell and Gauthier
Associates, Inc., Concord, MA).
Simulations were run on a VAX 8530
(Digital Equipment Co., Maynard, MA).
LaboratoryEstimation of
ParameterValues
Male Fischer-344 rats (200-250 g at time
of use) were obtained from Charles River
Breeding Laboratories (Wilmington, MA).
Table 4. Physiological parameters for a pharmaco-
dynamic model of organophosphates.
Parameter Mouse Rat Human
Bodyweight, kg 0.03 0.22
Alveolarventilation, 1/hr 1.04 4.57
Cardiac output, 1/hr 1.04 4.57
Organ volumes, percentage of bodyweight
Brain 1.47 1.16
Liver 6.17 4.00
Kidney 1.73 0.73
Richly perfused 2.00 2.00
Fat 8.00 7.00
Slowly perfused 65.74 68.66
Diaphragm 0.30 0.030
Lung 0.59 1.15
Venous blood 5.00 4.00
Arterial blood 2.50 2.00
60.6
354
302
2.14
4.00
0.43
3.43
17.00
55.14
0.3
0.86
5.70
2.00
Organ blood flows, percentage of cardiac output
Brain 3.00 3.00 13.40
Liver 25.00 25.00 27.00
Kidney 20.00 20.00 22.30
Richly perfused 28.00 27.96 20.00
Fat 9.00 9.00 3.60
Slowly perfused 14.40 14.40 13.10
Diaphragm 0.60 0.60 0.60
They were housed in plastic shoe box cages
with hardwood chip bedding, two per
cage, on a 12-hr light and dark cycle. Food
(Purina Formulab #5008) and water were
available ad libitum. Animals were quaran-
tined for 2 weeks to allow for acclimatiza-
tion and for quality assurance procedures
designed to ascertain animal health.
Quantitation of
Diisoproovlfluorophosphate
Metabolism
Enzymatic Hydrolysis. VmaX and K esti- mx m
mates were obtained by measuring fluoride
ion appearance in rat tissue-saline
homogenates (1:9 w/v) stirred constantly at
37°C (Table 3). Standards were prepared in
distilled water. Fluoride was measured with
an Orion 701 digital lonalyzer equipped
with an Orion 96-09 combination fluoride
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electrode (10). Heat-treated (30 min at
60°C) homogenates ofeach tissue were used
to measure nonenzymatic DFP hydrolysis.
V and Km were estimated from max m Lineweaver-Burk plots of the data (28).
V values for DFP metabolism deter- max
mined in rat tissues were scaled for mice and
humans by 0.7(body weight) (8,29). The
rat Km was used without adjustment for
mouse and human simulations.
Bimolecular Inhibition Rate
Constants. The rate of reaction of DFP
with AChE, BChE, and CaE, correspond-
ing to the rate of esterase inhibition, was
obtained by measuring decreases in tissue
homogenate esterase activity after addition
of DFP (Table 1). AChE activity was
assayed with a modification ofthe method
of Ellman (30). Assays were initiated by
adding 20 p of tissue-saline homogenate
(1:3 w/v) to 2.0 ml of substrate solution
(0.3 mM acetylthiocholine [Calbiochem,
San Diego, CA], 0.3 mM dithionitroben-
zoic acid [Calbiochem, San Diego, CA] in
0.05 M potassium phosphate buffer [Pfaltz
and Bauer, Stanford, CT]) that had been
previously warmed in a water bath at 37°C.
After rapid mixing, 0.3 ml of the
homogenate/substrate mixture was imme-
diately added to a temperature-controlled
cuvette (37) in a Gilford 2600 spectropho-
tometer (Oberlin, OH). The cuvette was
held for 1 min and then absorbence was
read at 0.1-min intervals for 1 min. DFP
(Sigma Chemical Co., St. Louis, MO) was
then added and the absorbence read at 412
nm at 0.1-min intervals for 5 min. The
bimolecular inhibition rate constant was
evaluated as
culations as inhibition reaction rates were
determined per gram oftissue.
Partiton Coefficients
Partition coefficients for DFP (Table 5)
were determined by the vial equilibration
technique (31,32). DFP was injected into a
closed vial containing heat-treated (60°C, 1
hr) rat blood or tissue homogenate at
37°C. After equilibration (2 hr), head space
DFP space was quantitated by gas chro-
matography. Reference vials containing
saline were treated identically.
Tissue-blood partition coefficients were
calculated by dividing the tissue-air value
by that for blood-air. Partition coefficients
determined for rat tissues were also used
for simulations of mouse and human data.
The muscle-blood partition was used for
the lumped, slowly perfused compartment
and the liver-blood partition for the
lumped richly perfused compartment. The
partitioning ofparathion in the brain com-
partment was estimated from the data of
Eigenberg et al. Parathion and paraoxon
partitions in other tissues were determined
in vitro by equilibrium dialysis (33).
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Table 5. Partition coefficients.
Partition coefficients
Tissue DFP Parathion Paraoxon
Blood-air 12.57 NA NA
Brain-blood 0.67 4.56a 2.31a
Liver-blood 1.53 5.21 6.62
Kidney-blood 1.63 5.21 6.62
Richly perfused
blood 0.67 5.21 6.62
Fat-blood 17.6 101.2 10.22
Slowly perfused
blood 0.77 2.55 3.62
Diaphragm-blood 0.77 2.55 3.62
DFP, diisopropylfluorophosphate.8Estimated from
Eigenberg (37).
Results
Diisopropylfluorophosphate
Pharnacokinetics and
Acetylcholinesterase Inhibition inMice
Several published studies of DFP pharma-
cokinetics and AChE inhibition in mice
and rats were analyzed with the simulation
model. This included both single and mul-
. (b)
1.00 1.50 2.00 2.50
where k. is the bimolecular rate constant
(M'min"); [S] is the substrate concentra-
tion (M); V is the reaction velocity
(mole/min/g tissue), Vo is the AChE activ-
ity at time zero (mole/min/g tissue); tis the
duration (min) ofincubation; [DFP] is the
concentration of DFP (M), Km is the
Michaelis-Menten constant (M). The
appropriate volume ofDFP was added and
there was a plot of absorbence at 412 nm
versus time obtained. Slopes oftangents to
the curve provided the velocity ofthe sub-
strate hydrolysis reaction. The bimolecular
rate constants for BChE and CaE were
determined as for AChE, except that the
substrates were butyrylthiocholine and p-
nitrophenylacetate, respectively. The con-
centration of tissues used in tissue
homogenates was not a factor in these cal-
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Figure 3. Time-course of free diisopropylfluorophosphate concentration (DFP)(milligrams per liter) in plasma and
brain in male mice (Dublin ICR) after tail vein injection of 1 mg DFP/kg. Each datum represents the mean (±1 SD)
of five animals. Data from Martin (34). Solid line depicts computer simulation generated with the physiologically
based pharmacokinetic model.
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tiple dosing regimens. Martin (34) injected
Dublin ICR male mice (Dominion
Laboratories, Dublin, VA) via the tail vein
with 1 mg tritium [3H]DFP/kg. To mea-
sure free, bound, and metabolized
[3H]DFP, tissues from treated animals
were homogenized, centrifuged, and
extracted with ethyl acetate. The ethyl
acetate extracts were then either counted
with liquid scintillation for total radioactiv-
ity, concentrated under nitrogen (N2), and
subjected to thin-layer chromatography, or
the aqueous portion that remained after
extraction was solubilized and counted for
radioactivity.
A dominant characteristic of DFP
pharmacokinetics well illustrated by this
study is rapid clearance of free DFP from
blood and brain. Free DFP in plasma had
largely disappeared within 1 min of iv
injection (Figure 3a). In brain, free DFP at
approximately 1 min post injection had
fallen to a small fraction of its peak con-
centration (Figure 3b). The PBPK model
accurately simulated these data (Figure
3a,b). At time points greater than 5 min
though, a less rapid disappearance of DFP
from blood and brain than was predicted
by the model was measured experimentally
(Figure 3c,d). However, the area under the
plasma and brain concentration-time
curves at these later time points repre-
sented less than 3% of the total free DFP
dose to these tissues. It is possible that the
apparent failure of the model to accurately
track the free DFP concentration at later
time points may be due to the measure-
ment of3H activity as a surrogate for the
actual concentration offree DFP. Some3H
activity inferred to be free DFP may, in
fact, have been a DFP metabolite or prod-
ucts ofcovalent binding.
Martin (34) also measured AChE inhi-
bition in mice after iv injection of DFP.
The nadir of AChE activity occurred
within 1 min in plasma and at about 5
min in brain (Figures 4a,5a). After opti-
mization of AChE resynthesis, PBPK
model simulations of these data were rea-
sonably accurate from the time of injec-
tion through 24 hr (Figures 4b,5b). The
PBPK model was initially structured so
that plasma and brain tissue AChE activi-
ties would return to 100% of control lev-
els in about 3.75 days. Martin (34) found,
however, that 7 days after a single iv injec-
tion of 1 mg DFP/kg, brain AChE activity
in the mouse was only about 80% of the
preexposure level (Figure 5c).
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Figure 4. Time-course of plasma acetylcholinesterase
(AChE) activity in male mice (Dublin ICR) after tail vein
injection of 1 mg diisopropylfluorophosphate/kg. Data
are expressed as a fraction of control activity. Each
datum represents the mean (±1 SD) of five animals.
Data from Martin (34). Solid line depicts computer
simulation.
Acetyicholinesterase Inhibition in
RatPlasmaandBrainafter
Repeated Dosingwith
Di'isopropylfluorophosphate
Michalek (24) injected male Wistar rats sc
with DFP everysecond dayfor 22 days. The
first dose was 1.1 mg DFP/kg, and subse-
quent doses were 0.7 mg/kg. Five rats (four
DFP and one vehicle exposed) were
sacrificed for measurement ofbrain AChE
activity at 1.5 and 24 hr after the 1st, 2nd,
4th, 6th, 9th, and 12th DFP doses and at
various intervals (48 and 72 hr; days 7, 14,
28, and 35) after the last dose. Traina and
Serpietri (25) measured the effect of DFP
on plasmaAChE activity using the same rat
strain anddosing regimen as Michalek (24).
Traina and Serpietri (25) found that
plasma AChE activity in the rat fell rapidly
after sc injection ofDFP (Figure 6a). AChE
activity was about 15% ofcontrol 1.5 hr
after the initial dosing and about 70% of
control at 24 hr. Simulations ofthese data
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Figure 5. Time-course of brain acetylcholinesterase
(AChE) activity in male mice (Dublin ICR) after tail vein
injection of 1 mg diisopropylfluorophosphate/kg,
expressed as a fraction of control (AChE) activity. Each
datum represents the mean (±1 SD) of five animals.
Data from Martin (34). Solid line depicts computer
simulation.
(Figure 6a) were obtained after optimiza-
tion ofthe rate ofabsorption of DFP into
blood following a single sc injection.
Simulation of the initial fall in plasma
AChE activity was particularly sensitive to
this parameter. The rate ofAChE synthesis
and first-order loss were also visually opti-
mized against these data. This was critical to
successful simulation ofthe return ofAChE
activity towards control levels obtained after
a single sc injection. Once obtained in this
manner the model was used for simulation
ofthe multiple dosing scenario (Figure 6b).
Plasma AChE act'ivities measured (25)
after the last subcutaneous dose of DFP
(day 22) are suggestive of an overshoot of
the control level. Plasma AChE activity
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Figure 6. Plasma acetylcholinesterase (AChE) activity
in male rats (Wistar) injected sc with diisopropyl
fluorophosphate (DFP) (a first dose of 1.1 mg DFP/kg,
then 0.7 mg/kg every other day for 22 days). Data are
expressed as a fraction of the control AChE activity.
Plasma AChE activity was assayed at 1.5 and 24 hr
after each dose of DFP. Each datum represents the
mean (±1 SD) of four animals. Data from Traina and
Serpietri (25). Solid line depicts computer simulation.
had returned to a stable 100% of the con-
trol level by 5 to 6 days after the last DFP
dose (Figure 6b). There was no provision
in the PBPK model for simulation ofsuch
an overshoot, though this phenomenon has
been modeled for other systems, as in the
case ofglutathione replacement after deple-
tion by toxicant exposure (35,36).
The pattern of brain AChE activity
after subcutaneous DFP dosing (24) was
similar to that seen in plasma (25), though
the extent of recovery between doses was
smaller (Figure 7a,b). The recovery of
brain AChE activity after termination of
DFP dosing was prolonged. For example,
activity was only about 65% ofcontrol 28
days after the last dose of DFP. When the
basal rates ofAChE degradation and syn-
thesis were optimized for acceptable simu-
lation of brain AChE activity during
dosing (Figure 7a), simulation ofAChE
activity after termination of dosing pre-
dicted a more rapid return than was
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Figure 7. Brain acetylcholinesteraw
rats (Wistar) injected sc with diisoi
phate (DFP) (a first dose of 1.1 mg
mg/kg every other day for 22 days). D
as a fraction of control AChE activity.
itywas assayed at 1.5 and 24 hraftei
datum represents the mean (±1 SD)o0
from Michalek et al. (24). Solid line
simulation.
observed (Figure 7b). Model
tated a relatively rapid and
return ofbrain AChE activity
control level. The data sugg
that a full return ofbrain Ac
the control level is amultipha2
Acetyichofinesterase Inhibi
Humans
Simulations ofboth the acutl
DFP exposures provide p
AChE and BChE inhibition
near the experimentally deter
values. The time-course c
BChE inhibition after an act
pg DFP/kg bw resulted ir
AChE inhibition at 24 hr a
BChE inhibition at 4 hr (Fij
difference in the degree and
mum enzyme inhibition
reflection of the 20-fold dif
bimolecular inhibition rate
the two enzymes. The simuk
a good prediction ofAChE inhibition for
all the acute time-course inhibition data.
Simulations of red blood cell
(RBC)-AChE and plasma BChE inhibi-
tion in four people injected at four differ-
ent doses of DFP covering 10 to 54 pg
DFP/kg bw compared favorably to the
actual enzyme activity measured in these
individuals at 24 hr (Figure 8b). The great-
est discrepancy between the simulations
and data occurred for the RBC-AChE at
54 jig/kg dose and the 10 jig/kg plasma
24.00 30.0 BChEvalues (Figure 8b).
The model predictions ofAChE and
BChE inhibition resulting from repeated
im injections of 20 pg DFP/kg bw were
representative of the overall trend of
enzyme inhibition (Figure 8c). During the
first 5 days of repeated dosing, the actual
AChE activity dropped rapidly from 100%
ofbaseline to approximately 50% activity
and then at a much slower rate to a final
enzyme activity of30%. The simulation of
these data predicted a inhibition ofapproxi-
mately 40% during the initial 5 days of
dosing that was sustained throughout the
480 600 rest ofthe exposure period. BChE activity
dropped immediately during the first 5 days
to 15% of the basal enzyme activity and
se (AChE) in male remained at this level during the exposure
propylfluorophos- period (Figure 8c). The simulation pre-
DFP/kg, then 0.7 dicted a 10 to 20% greater initial drop in
BraiareChErestied enzyme activity then was actually measured.
r DFPdosing. Each Parathion and ParaoxonKinetics in
f six animals. Data the Rat
depicts computer Eigenberg (37) measured concentrations of
PA and PO in brain, liver, and blood, as
well as PA in fat, following an iv injection of
structure dic- PA at a dose of3 mg/kg. Simulation of PA
I monophasic and PO kinetics in brain, liver, and blood
to the original after iv injection of3.0 mg PA/kg were in
,est, however, general agreement with the published data
hE activity to (Figures 9,10). The simulation of PA kinet-
sic process. ics in fat tissue (Figure 11) required the
addition ofdiffusion limitation to this com-
ition in partment to achieve agreement with the
experimental data.
e and repeated
redictions of Discussion
l that are very The Michaelis-Menten parameters used to
.mined human describe DFP hydrolysis and the bimolecu-
)f AChE and lar inhibition rate constants describing
ute dose of33 BEST inhibition were obtained in vitro.
i a maximum The success ofsimulations of in vivo DFP
Lnd maximum pharmacokinetics data (Figure 3a,b) sug-
gure 8a). This gests that the parameter values measured in
time to maxi- vitro are reasonable estimates ofthe corre-
is a direct sponding in vivo values. In vitro estimation
ference in the ofin vivoparameter values was also used by
constants for Dedrick (3). They developed a PBPK model
ation provided for arabinofuranosylcytosine (ARA-C) and
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Figure 8. (a) Time-course of red blood cell acetylcholinesterase (AChE) and plasma butyrlcholinest
activities in a human after an im injection with 33 pg diisopropylfluorophosphate (DFP)/kg. (b) Twe
values for red blood cell AChE and plasma BChE activities in four humans after an im injection with f
pg DFP/kg. (c) Average values for the time-course of red blood cell AChE and plasma BChE activities
subjects after daily im injections with an average of 20 pg DFP/kg/day. (d) Predicted inhibition of
AChE activity after an acute im dose of 20 pg DFP/kg/day. Data for a, b, and c are expressed as a fra
trol activity. Solid lines depict computer simulation. Data from Grob et al. (47).
its metabolite, arabinofuranosyluracil in
four species and used rates of ARA-C
metabolism measured in vitro. However,
Reitz (38) found significant in vitro and in
vivo differences in the rates of methylene
chloride metabolism. Clearly, this problem
must be considered on a case-by-case basis.
Good agreement between in vitro and in
vivo metabolic rates might be expected
when the enzyme is soluble and its activity
is not directly dependent on cofactor con-
centration (e.g., phosphorylphosphatases)
(17). In such cases it should be relatively
easy to create an in vitro milieu functionally
similar to the in vivo milieu. On the other
hand, some enzymes are embedded in cellu-
lar membranes, have specific orientations
with respect to other enzymes that pre-
process substrates, and have activities highly
dependent on cofactor concentrations (e.g.,
cytochrome P450) (39). Activities of the
latter type may be greatly affected by tissue
homogenization and dilution in buffer. The
results obtained in this study and in the
studies of Dedrick (3) and Reitz (38) are
consistent with this expectation.
The rate ofAChE inhibition
tion of the bimolecular rate co1
The ki for AChE was determi
brain homogenate and this valu(
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enzyme activity. The rat ki for l
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also used for mice. This approach was also
used for the DFP-esterase inhibition rate
constants for CaE and BChE (see section
on model development). The ability ofthe
PBPK model to simulate AChE inhibition
in mice and rats (Figures 4-7) indicates
that the variance in these rate constants
among tissues and species is not large.
Andersen (40) found the rates ofinhibition
for solubilized AChE from the cerebral cor-
tex ofmice was within 20% ofthe rate for
rats.
40 50 One goal ofthis research effort was to
predict the kinetics and AChE inhibition
not only after an acute exposure to DFP,
but also after repeated doses. A good simu-
lation of the experimental data for plasma
and brain AChE inhibition in rats during
repeated subcutaneous administration of
DFP*was achieved (Figures 6,7). The
AMMA4W experimentally measured return of brain
AChE activity was much slower than the
rate ofenzyme resynthesis that was used in
the model. If the brain AChE resynthesis
rate was decreased in the model to agree
40 50 with the rate ofexperimentally determined
postexposure synthesis, then predictions of
brain AChE activity during DFP dosing
terase IChE) would be underestimated.
,nty-four hour The experimentally determined activity
from 10 to 54 ofAChE in brain after each DFP dose was in 35 human
human brain reproducible, yet the levels ofAChE at the action ofcon- 48- and 72-hr time points at the end ofall
repeated dosing indicated there was an alter-
ation in the mechanisms controlling enzyme
synthesis. For the model to predict the
is a func- return ofbrain AChE to normal levels of
nstant, ki. activity after repeated dosing, it would be
ned in rat necessary to address the effects ofdown reg-
e was then ulation of AChE receptors on AChE
having this enzyme synthesis rates. The simulation of
AChE was AChE resynthesis used the preexposed level
ofAChE activity as a reference in setting the
rate of resynthesis. This assumed that the
25.0 30.0
Figure 9. Simulated concentration of diisopropylfluo-
rophosphate in human brain (mg/I) after a 5-min inhala-
tion at 50 ppm. The level of plasma A esterates for
curve A was 1.5 times the scaled activity; for curve B it
was the scaled level of activity; and for C, it was 50%
ofthe scaled activity.
4 6
Time (hours)
Figure 10. Time-course of parathion in blood, liver, and
brain in (pg/ml) for 8 hr after an iv injection of parathion
at a dose of 3 mg/kg. Each data point represents the
mean of four rats. Data from Eigenberg etal. (37).
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receptor affinity and impetus to return
AChE to control tissue levels was unaltered.
If the receptor numbers and affinities are
affected by repeated dosing with DFP, it
would alter the rates ofAChE resynthesis
experimentally, which would require a
change in the model parameter controlling
AChE synthesis. This effect is believed to be
a response to excessive tissue concentrations
ofacetylcholine afterAChE inhibition (41).
Clarification ofthe mechanism ofthis
tolerance has involved the measurement of
receptor binding and numbers. Binding of
quinuclidinyl benzilate, a muscarinic
affinity label, has been shown to decrease in
affinity and density in the striatum of rats
following chronic cholinesterase inhibition
with DFP (42). Yamada (43) was able to
demonstrate a correlation between and a
dose-dependent decrease in muscarinic
receptors, AChE activity, and choline
uptake in regions ofthe brain and gastroin-
testinal tract ofguinea pigs treated repeat-
edlywith DFP. This effect was antagonized
byphysostigmine and atropine.
Simulations of the 24-hr recovery of
brain AChE after repeated DFP dosing
were well within one standard deviation of
the data during the series ofDFP doses and
only failed to predict brain AChE levels
after dosing had ceased. This could be due
to the experimental protocol chosen by
Michalek (24), where 48 hr were allowed
between each successive dose of DFP.
Ehlert (42) has shown the half-time for the
loss of muscarinic binding sites to be
approximately 1.6 days. The difference
between the frequency of DFP dosing
Michalek (24) used (i.e., which we have
simulated) and the rate ofchange in recep-
tor numbers and affinity may have been
lessened by the repeated dosing until after
the completion ofdosing.
While there was a good prediction of
DFP pharmacokinetics shortly after injec-
tion that accounted for greater than 95% of
the material injected, the simulation and
data became more divergent at longer times
after dosing. After the initial injection of
DFP, the major model parameter affecting
the disappearance ofcompound from the
animal is AEST hydrolysis activity. It
would be expected that enzymatic hydroly-
sis of DFP would continue to decrease
blood and tissue concentrations until there
is total disappearance of the compound.
The experimental data showed no differ-
ence in plasma DFP concentrations
between 15 and 30 min after injection and
only a decrease in DFP concentration of
32% in brain. Those BEST enzymes with
the highest affinity for DFP already would
have become inhibited at this time and
their low molar concentration then would
have very little effect on the overall kinetics
of DFP. Because the model and data both
predict the amount of DFP present in
blood and brain to be in the picogram per
milligram range within minutes of injec-
tion, it is possible that the difference
between the data and simulations are due to
inexact compound identification involved
in using the combination ofradiolabel and
chemical extraction to quantitate very low
concentrations ofDFP.
The PBPK model initially developed to
describe the kinetics ofDFP and inhibition
ofAChE in the rodent was successfully
scaled to simulate data from humans repeat-
edly treated therapeutically with DFP. It was
possible to predict the time course ofinhibi-
tion of RBC AChE and plasma BChE in a
male human injected intramuscularly with a
33 pg/kg dose of DFP and these enzyme
activities at 24 hr in four different humans
injected with DFP at doses from 10 to 54
pg/kg. By using the data from human stud-
ies to validate the model, it is possible to
simulate the amount ofAChE inhibition in
other target organs for which there are no
human data (Figure 12). This is significant,
because itprovides a means ofpredicting OP
effects in the target organs ofhumans for
which there will probably never be data. The
development of this model to predict the
human response to organophosphate expo-
sure provides a method ofmodeling possible
therapeutic or prophylactic approaches for
organophosphate exposure in humans.
The model was exercised for a hypo-
thetical inhalation exposure of humans to
50 ppm DFP for 5 min. Because CaE has
been shown to be an important
detoxification route for soman (20), a sim-
ulation of human exposure to DFP was
conducted with the activity of CaE
decreased by a factor of 10, which is the
activity expected in humans (44). The
effect ofthis alteration ofCaE levels on the
kinetics and inhibition ofAChE was negli-
gible due to the much lower affinity ofCaE
for DFP relative to the other enzymes pre-
sent (Table 1). The parameter that did have
an effect on DFP blood and brain kinetics
was AEST activity in the blood. The levels
ofAEST in blood were decreased by one-
half and increased by one-half over the
amount that was scaled by (bodyweight)0.7
from rats to humans. A 50% decrease in
AEST activity in blood caused a 16%
increase in the peak concentration of DFP
in brain. In contrast, increasing DFP AEST
activity by 50% caused an 9.5% decrease of
DFP in blood and a 13% decrease in brain.
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Figure 11. Time-course of parathion in fat (pg/ml) for
24 hr after an iv injection of paraoxon at a dose of 3
mg/kg. Each data point represents the mean of four
rats. Data from Eigenberg et al. (37).
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Figure 12. Time-course of paraoxon in liver, brain, and
blood in (pg/ml) 1 to 3 hr after an iv injection of
parathion at a dose of 3 mg/kg. Each data point repre-
sents the mean of four rats. Data from Eigenberg et al.
(37).
The PBPK model for DFP was success-
fully modified to describe the time-course
ofparathion and paraoxon in blood, liver,
and brain, and the time-course for
parathion in fat. A preliminary validation
of the model was conducted with data
obtained from the literature and collected
in laboratory studies. It was possible to
provide a reasonably good simulation of in
vivo data obtained from the literature, but
this required adjustment ofenzymatic val-
ues obtained in the literature. With further
validation of the model, it will be possible
to predict the inhibition ofAChE in the
different tissue compartments of the target
organs and use this model to provide pre-
dictions of the degree ofAChE inhibition
in occupational situations where humans
may be exposed. This will then provide a
basis for using the model to perform risk
assessments ofdifferent exposure scenarios.
The PBPK model for OPs is in effect a
quantitative hypothesis specifying the fac-
tors controlling OP pharmacokinetics in
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rats, mice, and humans. Once its parame-
ters have been set to realistic values, the
ability of the model to simulate real data
becomes a test ofthe hypothesis. Failure to
accurately simulate data suggests that model
structure, the hypothesis, needs refinement.
Iterations of this process (i.e., model
refinement, predictive simulation, labora-
tory experimentation) can be exploited to
advance the understanding ofthe biological
determinates of OP biodistribution. This
general paradigm has recently been dis-
cussed by Clewell andAndersen (45).
The present model for OPs does not
simulate toxicity per se. Instead, AChE
inhibition is simulated as an index of the
likelihood of toxic effect (2). The acute
toxicities of some OP agents may not be
due to acetylcholine overload but rather to
actions at sites other than AChE (46). In
these cases, simulation ofthe concentration
of free OP in target tissues would be
expected to provide an index correlated
with toxicity. For OPs whose primary
mechanism of acute toxicity is not AChE
inhibition, it would be desirable to extend
the current PBPK model to explicitly
describe the OP-tissue interaction most
directly correlated with toxicity.
PBPK models are useful in risk assess-
ment because their structure is amenable to
cross-species scaling or to simulate exposure
scenarios that cannot be tested otherwise. A
PBPK model validated for experimental
animals and appropriately scaled to humans
is theoretically capable ofsimulating phar-
macokinetic behavior in humans. This
assumes that the model structure appropri-
ate for the experimental species is also
appropriate for humans. Physiological para-
meters such as organ volumes, organ blood
flows, and pulmonary ventilation rates are
well characterized for humans as well as for
common experimental animals. Scaling of
toxicant-specific parameters can be more
problematical. Some success in scaling of
PBPK models has been achieved by assum-
ing that metabolic rates [e.g., Vmax, scale in
proportion to body surface area (8)]. With
respect to the DFP model, it is not clear a
priori how the DFP-esterase bimolecular
inhibition rate constants should scale from
rodents to humans. The ability demon-
strated in rats and mice to successfully use
in vitro estimates ofparameter values for
simulation of in vivo data suggested the
same approach would work in the human
version of the model. Moreover, the simi-
larity of inhibition rates for solubilized
AChE from the cerebral cortex ofmice and
rats (40) implies that some parameter val-
ues may be relatively insensitive to large
changes in bodyweight.
In summary, the model structure used
in the present study is clearly relevant to
humans for a variety of OPs (2) and the
data required for scaling is explicitly
specified by this structure. Application of
the present model to other OPs ofconcern
for human exposure may, therefore, be a
relatively straightforward task.
Appendix 1: Conversion of In
Vitro Measurements for In
Vivo Modeling
The two calculations shown here provide
an example ofthe dimensional analysis to
convert in vitro DFPase values of Vmax and
Km for extrapolation to in vivo modeling.
The values in Table 3 for V are reported max
in milligrams per hour. These values were
determined in vitro in grams per minute
per gram oftissue. The in vitrovalue for Km
was determined in nanomoles per liter. An
example ofconverting in vitro values to in
vivo values for the liver is, for Vmax, 9.02
mole DFP/min/g liver x 60 min/hr 40 g
liver/kgbw x0.184 g/pmole x mg/I03g =
3983 mg/hrxkg and, for Km, 1.29
mmoles/l x 184mg/mmole = 237.36mg/l.
Appendix II: Description of
Pharmacokinetic Model
The mass balance differential equation for
DFP in brain is VBr x dCBr/dt = QBr x
(CABr- CVBr) - (V Brx CVBr)l(KmBr
+ CVBr) - KAChE x CAEBr x CBr -
KCaE x CCEBrx CBr- KBChE x CBEBr
x CBr, where VBr = volume ofbrain (liter);
CBr = concentration of DFP in the brain
compartment (mg/I); QBr = blood flow to
the brain (l/hr); CABr = DFP in arterial
brain (mg/I); CVBr = DFP in venous blood
leaving brain (mg/1); Vma. Br = maximum
rate of DFPase hydrolysis (mg/hr); KmBr =
Michaelis-Menten constant for DFPase in
brain (mg/i); KAChE = bimolecular rate
constant for DFP reaction with AChE (M-
hr)-I; CAEBr = AChE concen-tration in
brain (M); KCaE = bimolecular rate con-
stant for DFP reaction with CaE (M-hr)- ;
CCEBr = CaE concentration in brain (M);
KBChE = bimolecular rate constant for
DFP reaction with BChE (M-hr) I; and
CBEBr= BChE concentration in brain (M).
This equation is also used to describe DFP
in the liver, kidney, rapidly perfused, as well
as venous and arterial tissue compartments.
In the remaining compartments (lungs, fat,
slowly perfused, and diaphragm), the differ-
ential equation for DFP is VTx dCT/dt =
QTx (CAB - CT/PT), where VT= volume
of tissue (liter); dCT/dt = change in tissue
concentration with time (mg/hr); QT=
blood flow to tissue (l/hr); CAB = arterial
blood concentration (mg/1); CT= tissue
concentration (mg/1); and PT= tissue-to-
blood partition coefficient.
The differential equation to calculate
inhibited AChE activity in the different tis-
sue compartments is VBr x dAEBR/dt =
(KAChE x CAEBRx CBRM) - (KRABR x
AEBR - (KAABR x AEBR), where VBr =
volume ofbrain (1); KAChE = bimolecular
inhibition rate constant ofACHE (M-hr)-';
CAEBR = free AChE in brain (M); CBRM
= DFP in brain (M); KRABR = rate of
regeneration of inhibited AChE (hr-I);
AEBR = inhibited AChE (M); and KAABR
= rate ofaging ofinhibited AChE (hr-1).
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